Transvenous phrenic nerve stimulation to treat idiopathic central sleep apnea.

ABSTRACT:

Study objectives

Idiopathic central sleep apnea (ICSA) is a rare disorder diagnosed when known causes of central sleep apnea are excluded. No established treatments exist for ICSA, and long-term studies are lacking. We assessed the long-term effectiveness and safety of transvenous phrenic nerve stimulation in patients with ICSA.

Methods

In the remedē System Pivotal Trial, 16/151 (11%) participants with central sleep apnea were diagnosed as having ICSA. Patients were implanted and followed through 18 months of active therapy. Polysomnograms obtained at baseline and at 6, 12, and 18 months were scored by a central laboratory. Sleep metrics and patient-reported quality of life outcomes were assessed.

Results

Patients experienced moderate-severe central sleep apnea. The b

SUBMITTER: Javaheri S 

PROVIDER: S-EPMC7848930 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature